To cite this paper use one of the standards below:
The pyrrolo[2,1-f][1,2,4]triazin-4-amine scaffold is present in important contemporary pharmaceuticals, including remdesivir, the first FDA-approved antiviral drug for the treatment of COVID-19. Conventional synthetic approaches to remdesivir generally require pre-functionalization of the N-heterocycle under harsh reaction conditions.1 To date, only two reports have described the direct C7-functionalization of the pyrrolo[2,1-f][1,2,4]triazin-4-amine.2,3 In this context, we explored a new methodology employing functionalized 1,4-dihydropyridines (DHPs) as radical precursors for the generation of nucleophilic carbon-centered radicals, using (NH₄)₂S₂O₈ as the oxidant at 80 °C.4 Under these conditions, diethyl 4-(benzylcarbamoyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate afforded the corresponding C7-carbamoylated pyrrolotriazine in 70% isolated yield. Following optimization of the reaction conditions, a broad range of DHP derivatives, including sugar-substituted analogues, will be investigated to access novel C-nucleosides through direct C–H functionalization of the pyrrolotriazine core.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper